Search
Researchers gain insight into leptomeningeal metastasis, a devastating complication of advanced cancer.
Memorial Sloan Kettering Cancer Center (MSK) and Curadev Pharma, Inc., a biotechnology company developing novel immuno-oncology therapeutics, are expanding their collaboration through the MSK Therapeutics Accelerator program to advance the development of CRD3874-SI, Curadev’s first-in-class allosteric stimulator of interferon genes (STING) agonist for solid tumors.
Minimally invasive techniques, improved postoperative care, and a multidisciplinary approach help make Memorial Sloan Kettering Cancer Center’s rates of esophageal surgical morbidity and mortality among the country’s lowest.
MSK's Robert Motzer presented positive data from a phase III randomized study that assessed two different treatment combinations as first-line therapies that may benefit people with advanced kidney cancer.
Pediatric oncologists from around the world will gather in Lyon, France, from October 23 through 26, for the International Society of Paediatric Oncology’s annual meeting. Featuring new research and important discoveries — many led by MSK Kids researchers — the meeting will highlight the latest in the fields of pediatric oncology, including blood cancer, sarcoma, Wilms’ tumor, genomics, radiation oncology, and neuroblastoma.
Positive results from a clinical trial published in The New England Journal of Medicine show that the combination of the immunotherapy drugs ipilimumab (Yervoy™) and nivolumab (Opdivo™), produced significantly better outcomes than ipilimumab alone in patients with advanced melanoma. A second piece in the same issue from MSK details a dramatic response occurring after a single dose of the combination therapy.
Diane Reidy-Lagunes sits down with Mary Elizabeth Williams to discuss what it was like being part of a phase 1 clinical trial, how clear communication can affect health outcomes, how guilt often accompanies survival, and what not to say to a cancer patient.
Data from 25,000 patients is helping scientists answer this and many other important questions.
Lonny Yarmus, DO, MBA, has been appointed Head of the Division of Subspecialty Medicine in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). A physician-scientist and internationally recognized leader in interventional pulmonology and procedural innovation, Dr. Yarmus is widely known for his expertise in minimally invasive diagnostics and therapeutics, outcomes research, and multidisciplinary program development.
Experts at Memorial Sloan Kettering Cancer Center (MSK) have identified genome doubling in cancer and have correlated it to a worse prognosis across cancer types. Using MSK-IMPACT™ to analyze matched tumor and normal DNA, MSK researchers were able to identify an abnormality in tumors known as genome doubling. This doubling occurs in 28 percent of all cancers and could have significant implications for treatment options in the future.